BWA
FATE icon

Basecamp Wealth Advisors’s Fate Therapeutics FATE Stock Holding History

Basecamp Wealth Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$608 Buy
225
+116
+106% +$215 ﹤0.01% 1607
2026
Q1 		$131 Buy
+109
New +$133 ﹤0.01% 1910

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Basecamp Wealth Advisors's FATE Position: Q2 2026 in Review

Basecamp Wealth Advisors increased its Fate Therapeutics (FATE) stake by 106% in Q2 2026, buying an estimated $215 and bringing the position to 225 shares worth $608. The position accounts for ﹤0.01% of the portfolio, ranked #1607.

Basecamp Wealth Advisors first reported a position in FATE in Q1 2026 and has held it in 2 quarters since. 155 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Basecamp Wealth Advisors held 225 shares of Fate Therapeutics worth $608 as of Q2 2026.
  • Basecamp Wealth Advisors bought 116 Fate Therapeutics shares in Q2 2026, an estimated $215.
  • Fate Therapeutics made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1607 holding.
  • Basecamp Wealth Advisors first reported a position in Fate Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 155 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.